Home  |  Specialties | Resource Centers |  Learning Centers  |  CME  |  Contributor Recruitment
  Articles Images CME Advanced Search  Consumer Health Link to this site
You are in: eMedicine Specialties > Medicine, Ob/Gyn, Psychiatry, and Surgery > Infectious Diseases

Sepsis, Bacterial

Last Updated: May 26, 2006
Rate this Article
Email to a Colleague
Get CME/CE for article
Synonyms and related keywords: septic shock, bacteremia, septicemia, fever, cytokines, endotoxins, leukocytosis, pseudosepsis, urosepsis

  AUTHOR INFORMATION Section 1 of 10    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Author: Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York at Stony Brook School of Medicine; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD, MACP, is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Editor(s): Pranatharthi Haran Chandrasekar, MD, Director of Infectious Disease Fellowship, Professor, Department of Internal Medicine, Harper Hospital, Wayne State University School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Thomas M Kerkering, MD, Professor of Medicine & Microbiology, Department of Internal Medicine, Division of Infectious Disease, Brody School of Medicine at East Carolina University; Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Clinical Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital; and Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice

Disclosure


  INTRODUCTION Section 2 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Background: Sepsis is a clinical term used to describe a patient who has symptomatic bacteremia, with or without organ dysfunction. Sustained bacteremia, in contrast to transient bacteremia, may result in a sustained febrile response that may be associated with an organ dysfunction. Septicemia refers to the active multiplication of bacteria in the bloodstream that results in an overwhelming infection.

Pathophysiology: The pathophysiology of sepsis is complex and results from the effects of circulating bacterial products, mediated by cytokine release, occurring as a result of sustained bacteremia. Cytokines, previously termed endotoxins, are responsible for the clinically observable effects of the bacteremia on the host. Impaired pulmonary, hepatic, or renal function may result from excessive cytokine release during the septic process.

Frequency:

  • Internationally: Sepsis is a common cause of mortality and morbidity worldwide.

Mortality/Morbidity:

  • The outcome from sepsis depends on the underlying status and host defenses, prompt and adequate surgical drainage of abscesses, relief of any obstruction of the intestinal or urinary tract, and appropriate and early empiric antimicrobial therapy with the drug spectrum appropriate to the presumed septic source.

Race: No racial predisposition is found.

Sex: No sexual predisposition is found.

Age: Urosepsis is more common in elderly men due to benign urinary tract obstruction from prostatic hypertrophy.


  CLINICAL Section 3 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

History:

Physical:

Causes:

  DIFFERENTIALS Section 4 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography


Other Problems to be Considered:

Table 1. Clinical Conditions Associated With Sepsis and Its Mimics
Associated With Sepsis (Fevers ³ 102ºF)Associated With Sepsis (Fevers £ 102ºF)
Gastrointestinal tract source
Liver
Gallbladder
Colon
Abscess
Intestinal obstruction
Instrumentation

Gastrointestinal tract source
Esophagitis
Gastritis
Pancreatitis
Small bowel disorders
GI bleed
Genitourinary tract source
Pyelonephritis
Intra/perinephric abscess
Renal calculi
Urinary tract obstruction
Acute prostatitis/abscess
Renal insufficiency
Instrumentation of bacteriuric patient
normal/abnormal host)
Genitourinary tract source
Urethritis
Cystitis
Cervicitis
Vaginitis
Catheter-associated bacteriuria
(in normal hosts
without
genitourinary tract disease)
Pelvic source
Peritonitis
Abscess

Upper respiratory tract source
Pharyngitis
Sinusitis
Bronchitis
Otitis
Lower respiratory tract source
CAP* (with asplenic)
Empyema
Lung abscess

Lower respiratory tract source
CAP (normal host)
Intravascular source
IV-line sepsis
Infected prosthetic device
Acute bacterial endocarditis
Skin/soft tissue source
Osteomyelitis
Uncomplicated wound infections
Cardiovascular source
Acute bacterial endocarditis
Myocardial/perivalvular ring abscess
Cardiovascular source
Subacute bacterial
endocarditis

 Central nervous system source
Bacterial meningitis

* Community-acquired pneumonia

Adapted from: Cunha BA, Shea KW. Fever in the intensive care unit. Infect Dis Clin North Am 1996; 10: 185209.

Pseudosepsis

It is important to consider other causes or conditions that mimic the clinical and hemodynamic parameters of sepsis.

The causes of pseudosepsis need identification because they require supportive, rather than antimicrobial, therapy. Pseudosepsis is a common cause of misdiagnosis in hospitalized patients, particularly in the emergency department and in medical and surgical intensive care units.

The most common causes of pseudosepsis are as follows:

  • Gastrointestinal hemorrhage

  • Pulmonary embolism

  • Acute myocardial infarction

  • Acute pancreatitis (edematous or hemorrhagic)

  • Diuretic induced hypovolemia

  • Relative adrenal insufficiency
Table 2. Septic Syndromes, Noninfectious Conditions Mimicking Sepsis
Clinical Presentations
Mimicking Sepsis
Hemodynamic Parameters
Mimicking Sepsis
Hemorrhage Acute pancreatitis
Pulmonary embolismAnaphylaxis
Myocardial infarctionSpinal cord injury
PancreatitisAdrenal insufficiency
Diabetic (abdominal crisis) ketoacidosis
SLE flare with abdominal crisis
Ventricular pseudoaneurysm
Massive aspiration/atelectasis
Systemic vasculitis
Diuretic-induced hypovolemia

Before embarking on a workup for sepsis or beginning empiric antibiotics, it is critically important to first rule out the treatable causes of pseudosepsis early in the disease process. Fever, chills, leukocytosis, and a left shift, with or without hypotension, may be present with pseudosepsis. All causes of pseudosepsis produce Swan-Ganz catheter readings that are compatible with sepsis (eg, increased cardiac output, decreased peripheral resistance), which could misdirect the unwary clinician.

Table 3. Sepsis Syndrome Versus Sepsis


Sepsis Syndrome:
No Infection
  Sepsis: Bacteremia From
GI, GU, Pelvic, IV Source
ParametersNo Definite Source
Plus³ 1
Abnormalities
Proper ID/Process/Source
Plus³ 1Microbiologic
Abnormalities
Microbiologic
Positive buffy coat smear
or
2/3 or 3/3 (+) blood cultures
HemodynamicßPVR* 
 Ý CO LV|| dilatation
Laboratoryß Fibrinogenß WBC
 ßµ2 globulins ß PLTs
ß Albumin 
Negative blood
cultures excluding
contaminants
ÝFSP
Ý Lactate
Ý D-dimers
Ý PT/PTT§
Ý
WBC (with left shift)
Clinical £ 102ºF
±
Tachycardia
±
Respiratory alkalosis
±
Hypotension
³102ºF
orHypothermia
±
Mental status changes
±
Hypotension

*Peripheral vascular disease
Cardiac output
Fibrin split products
§Prothrombin time/partial thromboplastin time
||Left ventricular
Platelets

It is important to appreciate that otherwise healthy hosts with CAP virtually never present with hypotension or sepsis. Patients with decreased or absent splenic function may present with overwhelming pneumococcal sepsis. If an otherwise healthy patient with CAP presents with shock and all of the other causes of pseudosepsis are ruled out, then it must be assumed that the patient is a compromised host with impaired or absent splenic function.

Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Bibliography

Click for related images.

Related Articles


Continuing Education
CME available for this topic. Click here to take this CME.

Patient Education



  WORKUP Section 5 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Lab Studies:

  • Blood cultures
    • Obtain blood cultures for all patients at admission to demonstrate the causative organism responsible for infection. Negative blood culture results are also necessary to rule in pseudosepsis.
    • Blood culture isolates might suggest the underlying disease process. Bacteroides fragilis suggests a colonic or pelvic source whereas Klebsiella species or enterococci suggest a gallbladder or urinary tract source more frequently than an intra-abdominal source.
    • A CBC count usually is not helpful because of the numerous conditions that mimic sepsis (eg, pseudosepsis) that present with a leukocytosis of variable degrees of a left shift. Leukocytosis with a left shift is a nonspecific diagnostic finding. It is as common in noninfection as with infection.
  • Other
    • Obtain a urine Gram stain, urinalysis, and urine culture if urosepsis is suspected.
    • If central IV line sepsis is suspected, then remove the line and send the tip for semiquantitative bacterial culture. If the catheter tip culture results are positive and demonstrate 15 or more colonies, and if the catheter tip isolate matches the blood culture isolate, an infection associated with the central IV line is diagnosed.
    • Obtain a buffy coat of the white cells from peripheral blood stained by acridine orange, or use the Gram method to demonstrate bacteria responsible for the bacteremia or septic process. While the yield is low, stained buffy coat smears, if positive, are the best rapid test available to demonstrate organisms causing bacteremia. If the stained buffy coat smear is positive, it demonstrates the morphology of the bacteria causing the bacteremia, which provides rapid information on which to base empiric antimicrobial therapy.

Imaging Studies:

  • Chest radiograph is important to rule out pneumonia and diagnose the following other causes of pulmonary infiltrates:
    • Pulmonary drug reactions

    • Pulmonary emboli

    • Pulmonary hemorrhage

    • Primary/metastatic pulmonary neoplasms

    • Lymphangitic spread of malignancies

    • Large pleural effusions

    • Pneumothorax

    • Hydrothorax

    • Fluid overload

    • Congestive heart failure

    • Acute myocardial infarction
    • Acute respiratory distress syndrome should suggest an intra-abdominal source (eg, acute pancreatitis).
  • Ultrasound
    • Obtain an ultrasound of the abdomen if biliary tract obstruction is suspected based on clinical presentation.
    • The ultrasound in cholecystitis may show a thickened gallbladder wall or biliary calculi but no dilatation of the common bile duct.
    • Stones in the biliary tract can be seen in patients with cholangitis, but the common bile duct will be dilated.
    • An abdominal ultrasound is suboptimal for the detection of abscesses or perforated hollow organs.
  • CT scan or MRI
    • Use CT scan or MRI of the abdomen if a nonbiliary intra-abdominal source of infection is suspected through history or physical examination.
    • CT scan and MRI are superior to ultrasound in demonstrating all lesions except those related to the biliary tract.
    • An abdominal CT or MRI scan also is helpful in delineating intrarenal and extrarenal pathology.
  • Gallium or indium scan: This has no place in the initial workup of these patients, since patients who are septic are acutely ill by definition, and rapid diagnostic tests (eg, CT scan or MRI of the abdomen, ultrasound of the right upper quadrant) are time-critical, life-saving interventions.

Other Tests:

  • ECG: Obtain an ECG and cardiac enzymes in patients where the diagnosis of acute myocardial infarction (MI) is likely. Remember that certain patients may present with a silent, asymptomatic MI, which should be included in the differential diagnosis of otherwise unexplained fever, leukocytosis, and hypotension. Silent MIs are common in the elderly and in those who have had recent abdominal or pelvic surgery. They also occur frequently in individuals with alcoholism, diabetes, and uremic conditions.

Procedures:

  • If a substantial pleural effusion exists, perform a thoracentesis for diagnostic purposes.
  • Perform a paracentesis for patients with gross ascites.
  • Swan-Ganz catheter
    • Use data obtained via Swan-Ganz catheter to manage the fluid status of the patient and to assess left ventricular dysfunction in those patients with acute myocardial infarction.
    • Do not use Swan-Ganz hemodynamic parameters to diagnose sepsis. While most patients with sepsis demonstrate an increased cardiac output with a low peripheral vascular resistance, the converse is not true. Most patients presenting with Swan-Ganz readings compatible with sepsis without a definite intravenous abdominal or genitourinary (GU) source do not have sepsis, but rather a pseudosepsis, as described above.
Histologic Findings: There are no specific diagnostic findings caused by sepsis in various organs.

  TREATMENT Section 6 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical Care:

Consultations:

Diet:

Activity:


  MEDICATION Section 7 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Appropriate antimicrobial therapy depends on adequate coverage of the resident flora of the organ system presumed to be the source of the septic process. Empiric monotherapy regimens include imipenem, meropenem, cefoperazone, piperacillin/tazobactam, or sulbactam/ampicillin. Combination therapeutic agents include clindamycin or metronidazole plus either levofloxacin, aztreonam, trimethoprim/sulfamethoxazole (TMP-SMZ), or an aminoglycoside.

No one drug/regimen is superior to another. Alternative agents may be used alone or in combination providing they have a low reactive potential and a good adverse effect profile.

Drug Category: Antibiotics -- Used to treat various types of infection.

Empiric therapy for IV line infections

Since IV-line infections due to methicillin-resistant Staphylococcus aureus (MRSA) are infrequent, do not use vancomycin empirically for IV-line infections.

If coagulase-negative staphylococci are recovered from the blood, do not use vancomycin empirically to treat these patients, since this is a low-virulence organism. Treatment of coagulase-negative, staphylococcal central-line infection requires removal of the line and not empiric vancomycin therapy.

If a central-line due to MRSA or coagulase-negative staphylococcal infection cannot be removed for clinical reasons, then empiric suppressive vancomycin therapy is acceptable.

Minimize use of vancomycin in order to prevent the emergence of Enterococcus faecium, a vancomycin-resistant enterococcus (VRE).

Preferred monotherapy for IV line infections is imipenem, meropenem, cefoperazone, or cefepime.

Combination therapy should also be with an antistaphylococcal penicillin, eg, nafcillin or linezolid plus aztreonam, an aminoglycoside or a quinolone.

Empiric therapy for biliary tract infections (cholecystitis/cholangitis)

The main biliary tract pathogens are Escherichia coli, Klebsiella, or Enterococcus faecalis. Staphylococcal and anaerobic coverage are not needed in the biliary tract. Anaerobes are important only in diabetics with emphysematous cholecystitis due to Clostridium perfringens. Preferred monotherapy for biliary tract infections is with imipenem, meropenem, piperacillin, or cefoperazone.

Empiric therapy for intra-abdominal and pelvic infections

The main pathogens in the lower abdomen/pelvis are aerobic coliform gram-bacilli and B fragilis. Enterococci are permissive/opportunistic pathogens and do not require special coverage. Potent anti-B fragilis and aerobic gram-negative bacillary coverage are essential, in addition to surgical intervention when drainage or repair of intra-abdominal viscera is required.

Preferred monotherapy for intra-abdominal and pelvic infections is imipenem, meropenem, piperacillin/tazobactam, or ampicillin/sulbactam.

Preferred combination therapy for intra-abdominal and pelvic infections is clindamycin or metronidazole plus either aztreonam, levofloxacin, or an aminoglycoside.

Empiric therapy for urosepsis

The primary uropathogens are gram-negative aerobic bacilli, eg, coliforms or enterococci (E faecalis, not E faecium vancomycin-resistant enterococci [VRE]).

Pseudomonas aeruginosa, Enterobacter, and Serratia are rare uropathogens and are associated with urological instrumentation.

Preferred monotherapy for urosepsis due to aerobic gram-negative bacilli is with aztreonam, levofloxacin, third or fourth generation cephalosporins, or an aminoglycoside.

Preferred monotherapy for urosepsis due to enterococci (E faecalis) is with ampicillin or vancomycin (penicillin-allergic).

Empiric therapy for urosepsis due to unknown organisms is with piperacillin, imipenem, meropenem monotherapy or levofloxacin, aztreonam, or an aminoglycoside plus ampicillin.

Empiric therapy for other causes of sepsis

S aureus sepsis usually is associated with infection caused by devices or acute bacterial endocarditis (ABE). Empiric therapy may be with nafcillin, an anti-staphylococcal, cephalosporin, a carbapenem, linezolid, or clindamycin with or without rifampin.

Pneumococcal or meningococcal sepsis may be treated with penicillin G or a beta-lactam. If there is associated meningococcal meningitis, then the antibiotic selected should penetrate the cerebrospinal fluid and be given in meningeal doses.

Empiric therapy for sepsis of unknown origin

The usual sources of sepsis are from the distal gastrointestinal (GI) tract, pelvis, or GU tract. For IV-line infections, see above.

Organisms that should be covered from the GI/GU tract and pelvis include aerobic gram-negative bacilli (coliforms), B fragilis, and enterococci. (At least 90% of the organisms are E faecalis; not E faecium VRE.)

Preferred empiric monotherapy includes meropenem, imipenem, piperacillin/tazobactam, sulbactam/ampicillin, or cefoperazone.

Preferred empiric combination therapy includes (1) levofloxacin plus either clindamycin or metronidazole, (2) aztreonam plus either clindamycin or metronidazole, (3) cefepime plus either clindamycin or metronidazole, or (4) aminoglycoside plus either clindamycin or metronidazole.
Drug Name
Imipenem (Primaxin) -- For treatment of multiple organism infections in which other agents do not have wide spectrum coverage or are contraindicated due to potential for toxicity.
Adult Dose1 g IV q6h
Pediatric Dose<12 years: Not established; 15-25 mg/kg/dose IV q6h suggested
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with cyclosporine may increase adverse CNS effects of both agents; coadministration with ganciclovir may result in generalized seizures
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsAdjust dose in renal insufficiency; avoid use in children <12 years; avoid use in those with CNS disorders/seizures
Drug Name
Meropenem (Merrem) -- Semisynthetic carbapenem antibiotic that inhibits bacterial cell wall synthesis.
Adult Dose1 g IV q8h
Pediatric Dose<10 years: Not established
>10 years: Administer as in adults
ContraindicationsDocumented hypersensitivity to carbapenem or beta-lactams; first trimester of pregnancy
InteractionsProbenecid increases serum levels
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment; pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation of medication
Drug Name
Cefoperazone (Cefobid) -- Beta-lactam antibiotic that inhibits bacterial cell wall synthesis. A third-generation cephalosporin with antipseudomonal and antistaphylococcal activity. Only cephalosporin with anti-enterococcal (E faecalis) activity. Active against S aureus (MSSA), aerobic gram-negative bacilli, E faecalis, and B fragilis.
Adult Dose2 g IV q12h
Pediatric Dose<10 years: Not established
>10 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsAlcohol ingestion within 72 h induces disulfiramlike reaction
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsMay increase in PT or INR; may need prophylactic administration of AquaMEPHYTON 10 mg IM q1wk to all critically ill patients receiving any beta-lactam antibiotic
Drug Name
Levofloxacin (Levaquin) -- A quinolone that exerts a bactericidal effect by interfering with DNA gyrase in bacterial cells; highly active against gram-negative and gram-positive organisms.
Adult Dose500 mg IV q24h
Pediatric Dose<10 years: Not established
>10 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; pregnancy; breastfeeding
InteractionsAntacids, iron and zinc salts may reduce serum levels; administer antacids 1-2 h before or after taking
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsSuperinfections may occur with prolonged or repeated antibiotic therapy
Drug Name
Piperacillin/tazobactam (Zosyn) -- Semisynthetic extended-spectrum penicillin that inhibits bacterial cell wall synthesis by binding to specific PBPs; most effective of the antipseudomonal penicillins.
Tazobactam increases piperacillin activity against S aureus, Klebsiella, Enterobacter, and Serratia species; (greatest increase in activity against B fragilis) but does not increase anti-P aeruginosa activity.
Intra-abdominal and pelvic infections: The main pathogens in the lower abdomen and pelvis are aerobic coliform gram-bacilli and B fragilis. Enterococci are permissive and opportunistic pathogens and do not require special coverage.
Adult Dose4.5 g IV q8h (piperacillin 4 g/tazobactam 0.5 g)
Pediatric Dose<10 years: Not established
>10 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid increases piperacillin serum levels; synergistic effect with aminoglycosides; heparin increases risk of bleeding; may decrease efficacy of oral contraceptives; tetracycline may decrease effectiveness
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsRenal impairment; may interfere with platelet function
Drug Name
Sulbactam/ampicillin (Unasyn) -- A combination beta-lactam and beta-lactamase inhibitor that suppresses bacterial cell wall synthesis by binding to specific PBPs. Sulbactam increases effectiveness against beta-lactamase–producing microorganisms. Sulbactam increases the activity of ampicillin against S aureus, Klebsiella, Enterobacter, and Serratia species; greatest increase in activity against B fragilis.
Adult Dose3 g IV q6h (ampicillin 2 g / sulbactam 1 g)
Pediatric Dose<10 years: Not established
>10 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid increases serum levels; decreases effectiveness of oral contraceptives
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment
Drug Name
Metronidazole (Flagyl) -- Binds to ribosomes in bacterial cells. Highly active against most anaerobes including B fragilis, but not active against aerobic gram-positive or gram-negative organisms.
In intra-abdominal or pelvic infections, it must always be used in combination with another antibiotic active against aerobic gram-negative bacilli, which accompany B fragilis.
Adult Dose1 g IV q24h
Pediatric Dose<10 years: Not established
>10 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsPhenytoin and phenobarbital decrease serum levels; increases PT with warfarin; increases lithium levels and toxicity; cimetidine may increase serum levels
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsCategory D in first trimester of pregnancy; disulfiramlike reaction if taken within 72 h of alcohol consumption
Drug Name
Clindamycin (Cleocin) -- Exerts a bacteriostatic effect by interfering with bacterial metabolism at the ribosomal level. It is highly active against all staphylococci except MRSA. Some strains of S epidermidis are resistant. It is excellent against B fragilis but is not active against aerobic gram-negative bacilli. In mixed intra-abdominal or pelvic infections, it must always be used in combination therapy with an antibiotic active against aerobic gram-negative bacilli. No antienterococcal activity.
Adult Dose600 mg IV q8h
Pediatric Dose<10 years: Not established
>10 years: Administer same as in adults
ContraindicationsDocumented hypersensitivity; avoid in patients who have recently had C difficile, diarrhea, or colitis
InteractionsIncreased neuromuscular blockade
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in advanced cirrhosis; avoid in patients with preexisting inflammatory bowel disease; discontinue if diarrhea/colitis occurs during therapy
Drug Name
Aztreonam (Azactam) -- A monobactam that inhibits cell wall synthesis during bacterial growth. Active against gram-negative bacilli.
Adult Dose2 g IV q8h
Pediatric Dose90-120 mg/kg/d divided IV/IM q6-8h
ContraindicationsDocumented hypersensitivity
InteractionsTetracyclines may reduce effects of this medication
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal insufficiency; not active against B fragilis or enterococci
Drug Name
Moxifloxacin (Avelox) -- Inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription.
Adult Dose400 mg PO/IV qd
Pediatric Dose<18 years: Not recommended
>18 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; known Q-T prolongation, concurrent administration of drugs that cause Q-T prolongation
InteractionsAntacids, electrolyte supplements reduce absorption; loop diuretics, probenecid, cimetidine increase serum levels; NSAIDs enhance CNS stimulating effect; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT); ferrous sulfate decreases bioavailability (administer moxifloxacin 4 h prior or 8 h following ferrous sulfate); coadministration with drugs that prolong QTc interval (quinidine, procainamide, amiodarone, sotalol, erythromycin, tricyclic antidepressants) increase risk of life-threatening arrhythmia
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsIn prolonged therapy, periodically evaluate organ system functions (eg, renal, hepatic, hematopoietic); superinfections may occur with prolonged or repeated antibiotic therapy; fluoroquinolones have induced seizures in CNS disorders and have caused tendinitis or tendon rupture
Drug Name
Ertapenem (Invanz) -- Bactericidal activity results from inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins. Stable against hydrolysis by various beta-lactamases, including penicillinases, cephalosporinases, and extended spectrum beta-lactamases. Hydrolyzed by metallo-beta-lactamases.
Adult Dose1 g qd for 14 d if IV and 7 d if IM; infuse over 30 min if IV
CrCl <30 mL/min/1.73 m2: 500 mg IV qd
Pediatric Dose<3 months: Not established
3 months to 12 years: 15 mg/kg IV q12h; not to exceed 1 g/d
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity to drug or amide type anesthetics
InteractionsProbenecid may reduce renal clearance of ertapenem and increase half-life, but benefit is minimum and does not justify coadministration
Pregnancy B - Usually safe but benefits must outweigh the risks.
PrecautionsPseudomembranous colitis may occur; seizures and CNS adverse reactions may occur; when using with lidocaine to administer intramuscularly, avoid inadvertent injection into blood vessel; decrease dose in renal failure; serious and occasionally fatal hypersensitivity reactions may occur with beta lactams, caution with previous hypersensitivity reactions to penicillin, cephalosporins, other beta lactams, or other allergens; do not mix or coinfuse in same IV line as other medications; do not mix with dextrose-containing diluents
  FOLLOW-UP Section 8 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Further Inpatient Care:

Further Outpatient Care:

In/Out Patient Meds:

Transfer:

Complications:

Prognosis:

Patient Education:

  MISCELLANEOUS Section 9 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical/Legal Pitfalls:

  • The most important medical/legal concerns regarding sepsis treatment are to ensure that the patient indeed does have sepsis, to rapidly identify its source, and to implement effective treatments. The most frequent error committed in treating patients who are septic is failure to consider pseudosepsis as a cause of the presenting syndrome complex. Most causes of pseudosepsis are readily treatable and reversible if recognized and treated early.

Special Concerns:

  • Elderly patients may present with peritonitis and may not experience rebound tenderness of the abdomen. An acute surgical abdomen in a pregnant patient may be difficult to diagnose, but fortunately, most pregnant women are young, healthy, and physiologically strong. The most common cause of sepsis in pregnancy is urosepsis from an obstructed urinary tract, which may be due to the hormone effects of pregnancy on the ureters (hydroureters) and the mechanical obstructing effect of the uterus impinging upon the ureters.
  BIBLIOGRAPHY Section 10 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

  • Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999 Jun; 25(6): 556-66[Medline].
  • Bartlett JG: Intra-abdominal sepsis. Med Clin North Am 1995 May; 79(3): 599-617[Medline].
  • Bernard GR, Vincent JL, Laterre PF: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 Mar 8; 344(10): 699-709[Medline].
  • Bone RC: Sepsis and its complications: the clinical problem. Crit Care Med 1994 Jul; 22(7): S8-11[Medline].
  • Bryan CS, Reynolds KL, Brenner ER: Analysis of 1,186 episodes of gram-negative bacteremia in non- university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983 Jul-Aug; DA - 19831123(4): 629-38[Medline].
  • Carlet J: Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 1999 Jun; 13(2): 483-94, xi[Medline].
  • Carleton SC: The cardiovascular effects of sepsis. Cardiol Clin 1995 May; 13(2): 249-56[Medline].
  • Corriveau CC, Danner RL: Antiendotoxin therapies for septic shock. Infect Agents Dis 1993 Feb; 2(1): 44-52[Medline].
  • Cunha BA: Sepsis and its mimics. Intern Med 1992; 13: 48-55.
  • Cunha BA: Antibiotic treatment of sepsis. Med Clin North Am 1995 May; 79(3): 551-8[Medline].
  • Cunha BA: Bacteremia and sepsis. In: Rakel RE, Bope ET (Eds): Conn's Current Therapy 2003; 68-75.
  • Cunha BA: Empiric antimicrobial therapy for bacteremia: get it right from the start or get a call from infectious disease. Clin Infect Dis 2004 Oct 15; 39(8): 1170-3[Medline].
  • Cunha BA: Antibiotic Essentials. 5th ed. Royal Oak, Mich: Physicians Press; 2006.
  • Dellinger RP: Current therapy for sepsis. Infect Dis Clin North Am 1999 Jun; 13(2): 495-509[Medline].
  • Faro S: Sepsis in obstetric and gynecologic patients. Curr Clin Top Infect Dis 1999; 19: 60-82[Medline].
  • Gibaldi M: Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock. Pharmacotherapy 1993 Jul-Aug; 13(4): 302-8[Medline].
  • Klein NC, Cunha BA: Third-generation cephalosporins. Med Clin North Am 1995 Jul; 79(4): 705-19[Medline].
  • Kobayashi M, Tsuda Y, Yoshida T: Bacterial sepsis and chemokines. Curr Drug Targets 2006 Jan; 7(1): 119-34[Medline].
  • Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980 Mar; DA - 19800523(3): 344-55[Medline].
  • Kroesen S, Widmer AF, Tyndall A: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003 May; 42(5): 617-21[Medline].
  • Martin MA: Epidemiology and clinical impact of gram-negative sepsis. Infect Dis Clin North Am 1991 Dec; 5(4): 739-52[Medline].
  • Merrell RC: The abdomen as source of sepsis in critically ill patients. Crit Care Clin 1995 Apr; 11(2): 255-72[Medline].
  • Mieszczanska H, Lazar J, Cunha BA: Cardiovascular manifestations of sepsis. Infectious Disease Practice 2003; 27: 183-6.
  • Neu HC: General Therapeutic Principles. In: Infectious Diseases. Philadelphia, Pa: WB Saunders 1992: 153.
  • Opal SM, Cohen J: Clinical gram-positive sepsis: does it fundamentally differ from gram- negative bacterial sepsis? Crit Care Med 1999 Aug; 27(8): 1608-16[Medline].
  • Price CS, Hacek D, Noskin GA: An outbreak of bloodstream infections in an outpatient hemodialysis center. Infect Control Hosp Epidemiol 2002 Dec; 23(12): 725-9[Medline].
  • Rackow EC, Astiz ME: Pathophysiology and treatment of septic shock. JAMA 1991 Jul 24-31; 266(4): 548-54[Medline].
  • Ristuccia PA, Hoeffner RA, Digamon-Beltran M: Detection of bacteremia by buffy coat smears. Scand J Infect Dis 1987; 19(2): 215-7[Medline].
  • Sacks-Berg A, Calubiran OV, Epstein HY, Cunha BA: Sepsis associated with transhepatic cholangiography. J Hosp Infect 1992 Jan; 20(1): 43-50[Medline].
  • Sheagren JN: Corticosteroids for the treatment of septic shock. Infect Dis Clin North Am 1991 Dec; 5(4): 875-82[Medline].
  • Siegel JP, Stein KE, Zoon KC: 41 anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 327: 890.
  • Sriskandan S, Cohen J: Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am 1999 Jun; 13(2): 397-412[Medline].
  • Van Amersfoort ES, Van Berkel TJC, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003; 16: 379-414.
  • Waage A, Brandtzaeg P, Espevik T: Current understanding of the pathogenesis of gram-negative shock. Infect Dis Clin North Am 1991 Dec; 5(4): 781-91[Medline].
  • Wagner S: Transfusion-related bacterial sepsis. Curr Opin Hematol 1997 Nov; 4(6): 464-9[Medline].
  • Warren HS, Danner RL, Munford RS: Anti-endotoxin monoclonal antibodies. N Engl J Med 1992 Apr 23; 326(17): 1153-7[Medline].
  • Weinstein MP, Reller LB, Murphy JR: The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983 Jan-Feb; 5(1): 35-53[Medline].
  • Wenzel RP, Pinsky MR, Ulevitch RJ: Current understanding of sepsis. Clin Infect Dis 1996 Mar; 22(3): 407-12[Medline].
  • Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999 Jan 21; 340(3): 207-14[Medline].
  • Wiessner WH, Casey LC, Zbilut JP: Treatment of sepsis and septic shock: a review. Heart Lung 1995 Sep-Oct; 24(5): 380-92; quiz 392-3[Medline].
  • Yoshikawa TT: Empiric antimicrobial therapy. In: Antimicrobial Therapy in the Elderly Patient. New York: Marcel Dekker; 1994: 469.
  • Young LS: Gram-negative sepsis. In: Principles and Practive of Infectious Diseases. 3rd ed. New York: Churchill 1990: 611.

NOTE:
Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER

Sepsis, Bacterial excerpt

About Us | Privacy | Terms of Use | Contact Us | Advertise | Institutional Subscribers
© 1996-2007 by WebMD.
All Rights Reserved.